

Resource Summary Report

Generated by [RRID](#) on Jul 28, 2026

Ultra-LEAF(TM) Purified anti-human CD3

RRID:AB_11150592

Type: Antibody

Proper Citation

BioLegend Cat# 317326, RRID:AB_11150592

Antibody Information

URL: http://antibodyregistry.org/AB_11150592

Proper Citation: BioLegend Cat# 317326, RRID:AB_11150592

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Ultra-LEAF(TM) Purified anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone OKT3

Antibody ID: AB_11150592

Vendor: BioLegend

Catalog Number: 317326

Alternative Catalog Numbers: 317350, 317349, 317348, 317325, 317347

Record Creation Time: 20250820T012127+0000

Record Last Update: 20250820T104256+0000

Ratings and Alerts

No rating or validation information has been found for Ultra-LEAF(TM) Purified anti-human CD3.

No alerts have been found for Ultra-LEAF(TM) Purified anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 49 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Rainwater RR, et al. (2026) DNA-PKcs controls the cytotoxic T cell response to cancer and transplant allograft through regulating LAT-dependent signaling. Cell reports, 45(1), 116796.

Jones RD, et al. (2026) Tunable differentiation of human CD4+ and CD8+ T cells from pluripotent stem cells. Cell stem cell, 33(1), 73.

Luo C, et al. (2025) Integrated computational analysis identifies therapeutic targets with dual action in cancer cells and T cells. Immunity, 58(3), 745.

Li J, et al. (2025) Monocyte/macrophage-derived interleukin-15 mediates the pro-inflammatory phenotype of CD226+ B cells in type 1 diabetes. EBioMedicine, 120, 105946.

Chimote AA, et al. (2025) Potassium channels mediate the inhibitory effect of exosomes on anti-tumor immunity in head and neck cancer. bioRxiv : the preprint server for biology.

Ma K, et al. (2025) Succinate preserves CD8+ T cell fitness to augment antitumor immunity. Immunity.

Koliesnik I, et al. (2025) An IL-12 partial agonist sustains intratumoral lymphocyte activation and detoxifies systemic IL-12 therapy. Cell reports, 45(1), 116757.

Xiao Z, et al. (2025) Engineered T cells stimulate dendritic cell recruitment and antigen spreading for potent anti-tumor immunity. Cell reports. Medicine, 6(9), 102307.

Qiu Y, et al. (2025) Mannose metabolism reshapes T cell differentiation to enhance anti-tumor immunity. Cancer cell, 43(1), 103.

Zhang S, et al. (2025) Immunosequencing identifies signatures of T cell responses for early detection of nasopharyngeal carcinoma. Cancer cell, 43(8), 1423.

Xing R, et al. (2025) Enhanced formation of tertiary lymphoid structures shapes the anti-tumor microenvironment in hepatocellular carcinoma after FOLFOX-HAIC therapy. Cell reports. Medicine, 6(9), 102298.

Sagie S, et al. (2025) Lymphodepleting chemotherapy potentiates neoantigen-directed T cell therapy by enhancing antigen presentation. *Cell reports. Medicine*, 6(12), 102506.

von Locquenghien M, et al. (2025) Macrophage-targeted immunocytokine leverages myeloid, T, and NK cell synergy for cancer immunotherapy. *Cell*, 188(25), 7099.

Kanaoka D, et al. (2024) FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1 β to Activate p53 and Inhibit NF κ B Signaling. *Cancer research communications*, 4(2), 312.

Jia D, et al. (2024) Microbial metabolite enhances immunotherapy efficacy by modulating T cell stemness in pan-cancer. *Cell*, 187(7), 1651.

Dong B, et al. (2024) NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs. *Cancer immunology research*, 12(10), 1421.

Wu N, et al. (2024) MerTK+ macrophages promote melanoma progression and immunotherapy resistance through AhR-ALKAL1 activation. *Science advances*, 10(40), eado8366.

Wang L, et al. (2024) Induction of immortal-like and functional CAR T cells by defined factors. *The Journal of experimental medicine*, 221(5).

Wang Z, et al. (2024) Suppression of the METTL3-m6A-integrin α 1 axis by extracellular acidification impairs T cell infiltration and antitumor activity. *Cell reports*, 43(2), 113796.

Swatler J, et al. (2024) Protocol for isolation of tumor-derived extracellular vesicles and functional studies on human T cell subsets. *STAR protocols*, 5(2), 103011.